These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9161625)

  • 21. Adverse Drug Reactions in Patients Receiving Systemic Antifungal Therapy at a High-Complexity Hospital.
    de Souza MC; Santos AG; Reis AM
    J Clin Pharmacol; 2016 Dec; 56(12):1507-1515. PubMed ID: 27198583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic dysfunction following nafcillin and cephalothin therapy in a patient with a history of oxacillin hepatitis.
    Miller WI; Souney PF; Chang JT
    Clin Pharm; 1983; 2(5):465-8. PubMed ID: 6627877
    [No Abstract]   [Full Text] [Related]  

  • 23. Adverse drug reactions in hospitalized children in Fortaleza, Brazil.
    dos Santos DB; Coelho HL
    Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):635-40. PubMed ID: 16287200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007.
    Aagaard L; Weber CB; Hansen EH
    Drug Saf; 2010 Apr; 33(4):327-39. PubMed ID: 20297864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital.
    Geer MI; Koul PA; Tanki SA; Shah MY
    J Pharmacol Toxicol Methods; 2016; 81():323-34. PubMed ID: 27109493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse effects of neuromuscular blocking agents based on yellow card reporting in the U.K.: are there differences between males and females?
    Light KP; Lovell AT; Butt H; Fauvel NJ; Holdcroft A
    Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):151-60. PubMed ID: 16395661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia.
    Monogue ML; Ortwine JK; Wei W; Eljaaly K; Bhavan KP
    J Infect Public Health; 2018; 11(5):727-731. PubMed ID: 29526442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutropenia induced by semisynthetic penicillin.
    Carpenter J
    South Med J; 1980 Jun; 73(6):745-8. PubMed ID: 7394597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
    Yang W; Xiang YY; Xie YM; Shen H
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and economic impact of adverse drug reactions in hospitalized patients.
    Suh DC; Woodall BS; Shin SK; Hermes-De Santis ER
    Ann Pharmacother; 2000 Dec; 34(12):1373-9. PubMed ID: 11144691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency and preventability of adverse drug reactions in paediatric patients.
    Temple ME; Robinson RF; Miller JC; Hayes JR; Nahata MC
    Drug Saf; 2004; 27(11):819-29. PubMed ID: 15350153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use and safety of anthroposophic medications in chronic disease: a 2-year prospective analysis.
    Hamre HJ; Witt CM; Glockmann A; Tröger W; Willich SN; Kiene H
    Drug Saf; 2006; 29(12):1173-89. PubMed ID: 17147463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of adverse drug reactions detected by pharmacy and medical records departments.
    Johnstone DM; Kirking DM; Vinson BE
    Am J Health Syst Pharm; 1995 Feb; 52(3):297-301. PubMed ID: 7749958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse drug reactions reported to the drug and poison information center of Tehran, Iran.
    Saheb Sharif-Askari F; Saheb Sharif-Askari N; Javadi M; Gholami K
    PLoS One; 2017; 12(9):e0185450. PubMed ID: 28950006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
    Svendsen K; Wood M; Olsson E; Nordeng H
    Eur J Clin Pharmacol; 2018 May; 74(5):627-636. PubMed ID: 29290074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of Ceftriaxone Compared With Cefazolin or Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive
    Hamad Y; Nickel KB; Olsen MA; George IA
    Open Forum Infect Dis; 2024 Feb; 11(2):ofad662. PubMed ID: 38352150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies.
    Kongkaew C; Noyce PR; Ashcroft DM
    Ann Pharmacother; 2008 Jul; 42(7):1017-25. PubMed ID: 18594048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of adverse drug reactions reported to a poison control center between 2000 and 2007.
    Vassilev ZP; Chu AF; Ruck B; Adams EH; Marcus SM
    Am J Health Syst Pharm; 2009 Mar; 66(5):481-7. PubMed ID: 19233996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.